 |
449 Diseases |  |
58 Trials |
|
58 Trials |  |
3605 News |  |
| 12345678910111213...2425» |
- | Leukine (sargramostim) / Partner Therap, SurVaxM (SVN53-67/M57-KLH peptide vaccine) / MimiVax
Trial completion date: NCI-2015-00694: SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma (clinicaltrials.gov) - Mar 3, 2025
P2, N=66, Active, not recruiting, Sponsor: Roswell Park Cancer Institute
Trial completion date: Dec 2024 --> Jun 2025
- | Kimmtrak (tebentafusp-tebn) / Immunocore
Trial completion date, Trial initiation date, Trial primary completion date: Tebentafusp-tebn With LDT in Metastatic UM (clinicaltrials.gov) - Feb 11, 2025
P1/2, N=109, Not yet recruiting, Sponsor: Thomas Jefferson University
Trial completion date: Dec 2024 --> Jun 2025 Trial completion date: Aug 2026 --> Feb 2027 | Initiation date: Oct 2024 --> Apr 2025 | Trial primary completion date: Jul 2026 --> Jan 2027
- | AST-301 / University of Washington, Aston Sci., EpiThany
Trial completion date: Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian Cancer (clinicaltrials.gov) - Feb 6, 2025
P1, N=66, Active, not recruiting, Sponsor: University of Washington
Trial completion date: Aug 2026 --> Feb 2027 | Initiation date: Oct 2024 --> Apr 2025 | Trial primary completion date: Jul 2026 --> Jan 2027 Trial completion date: Dec 2024 --> Apr 2025
- | Leukine (sargramostim) / Partner Therap
Journal: Successful granulocyte-macrophage colony-stimulating factor inhalation therapy for recurrent autoimmune pulmonary alveolar proteinosis after lung transplantation: A case report. (Pubmed Central) - Jan 12, 2025
Sargramostim, a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) inhalation therapy, was recently approved for pharmaceutical use in Japan and shows promise as a treatment for autoimmune pulmonary alveolar proteinosis (APAP)...Inhaled GM-CSF may be a useful treatment option for APAP recurrence in patients who have undergone lung transplantation. CLINICAL TRIAL REGISTRATION: Pulmonary Alveolar Proteinosis GM-CSF Inhalation Efficacy Trial II registered to Japan Registry of Clinical Trials (jRCTs031220127).
- | Leukine (sargramostim) / Partner Therap
Biomarker, Journal: Biomarkers. (Pubmed Central) - Jan 12, 2025
CLINICAL TRIAL REGISTRATION: Pulmonary Alveolar Proteinosis GM-CSF Inhalation Efficacy Trial II registered to Japan Registry of Clinical Trials (jRCTs031220127). These findings suggest that age-associated exponential increases in neurodegeneration may underlie the contribution of aging to cognitive decline, including in AD, and that GM-CSF/sargramostim treatment may halt these effects.
- | Keytruda (pembrolizumab) / Merck (MSD), Leukine (sargramostim) / Partner Therap
Enrollment change, Trial termination: A Study of Sargramostim Plus Pembrolizumab with or Without Pemetrexed in Patients with Advance Non-small Cell Lung Cancer After Completion of Chemoimmunotherapy (clinicaltrials.gov) - Jan 3, 2025
P2, N=5, Terminated, Sponsor: Tufts Medical Center
These findings suggest that age-associated exponential increases in neurodegeneration may underlie the contribution of aging to cognitive decline, including in AD, and that GM-CSF/sargramostim treatment may halt these effects. N=83 --> 5 | Recruiting --> Terminated; Futility
- | Leukine (sargramostim) / Partner Therap, SurVaxM (SVN53-67/M57-KLH peptide vaccine) / MimiVax
Trial completion date, Trial primary completion date, Metastases: Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors (clinicaltrials.gov) - Dec 18, 2024
P1, N=14, Recruiting, Sponsor: Roswell Park Cancer Institute
N=83 --> 5 | Recruiting --> Terminated; Futility Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2025
- | Leukine (sargramostim) / Partner Therap
Trial completion date, Trial suspension, Trial primary completion date: Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the Lung (clinicaltrials.gov) - Nov 21, 2024
P1, N=20, Suspended, Sponsor: Mayo Clinic
Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2025 Trial completion date: Oct 2024 --> Jan 2026 | Withdrawn --> Suspended | Trial primary completion date: Oct 2024 --> Jan 2026
- ||| Zeltherva (galinpepimut-S) / SELLAS Life Sciences
Trial completion, Enrollment change, Metastases: Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers (clinicaltrials.gov) - Nov 19, 2024
P1/2, N=26, Completed, Sponsor: Sellas Life Sciences Group
Trial completion date: Oct 2024 --> Jan 2026 | Withdrawn --> Suspended | Trial primary completion date: Oct 2024 --> Jan 2026 Active, not recruiting --> Completed | N=90 --> 26
- | Zeltherva (galinpepimut-S) / SELLAS Life Sciences
Trial completion, Trial completion date, Trial primary completion date, Checkpoint inhibition: Using a Targeted Cancer Vaccine (Galinpepimut-S) with Immunotherapy (Nivolumab) in Mesothelioma (clinicaltrials.gov) - Nov 18, 2024
P1, N=10, Completed, Sponsor: Memorial Sloan Kettering Cancer Center
Active, not recruiting --> Completed | N=90 --> 26 Active, not recruiting --> Completed | Trial completion date: Jul 2025 --> Nov 2024 | Trial primary completion date: Jul 2025 --> Nov 2024
- | Zolinza (vorinostat) / Merck (MSD), Azedra (iobenguane I 131) / Lantheus, Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
Trial primary completion date: MIBG With Dinutuximab +/- Vorinostat (clinicaltrials.gov) - Nov 18, 2024
P1, N=45, Active, not recruiting, Sponsor: New Approaches to Neuroblastoma Therapy Consortium
Active, not recruiting --> Completed | Trial completion date: Jul 2025 --> Nov 2024 | Trial primary completion date: Jul 2025 --> Nov 2024 Trial primary completion date: Jun 2023 --> Feb 2024
- | Leukine (sargramostim) / Partner Therap
Journal: Repeated inhalation of GM-CSF by nonhuman primates induces bronchus-associated lymphoid tissue along the lower respiratory tract. (Pubmed Central) - Nov 16, 2024
Trial primary completion date: Jun 2023 --> Feb 2024 Long-term repeated inhalation of sargramostim led to iBALT formation in the lower respiratory tract, even at the clinical dose of 5
- || Leukine (sargramostim) / Partner Therap
Biomarker, Trial completion: Biomarker Validation Following Sargramostim Treatment in Parkinson's Disease (clinicaltrials.gov) - Nov 6, 2024
P1, N=11, Completed, Sponsor: University of Nebraska
Long-term repeated inhalation of sargramostim led to iBALT formation in the lower respiratory tract, even at the clinical dose of 5 Active, not recruiting --> Completed
- ||| Leukine (sargramostim) / Partner Therap, Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
Enrollment open, Combination therapy: NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial (clinicaltrials.gov) - Nov 6, 2024
P2, N=62, Recruiting, Sponsor: New Approaches to Neuroblastoma Therapy Consortium
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | Leukine (sargramostim) / Partner Therap
Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date: Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the Lung (clinicaltrials.gov) - Oct 29, 2024
P1, N=0, Withdrawn, Sponsor: Mayo Clinic
Not yet recruiting --> Recruiting N=24 --> 0 | Trial completion date: Jul 2025 --> Oct 2024 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jul 2025 --> Oct 2024
- | Leukine (sargramostim) / Partner Therap, Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
Trial completion date, Combination therapy: ANBL19P1: Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL) (clinicaltrials.gov) - Oct 22, 2024
P2, N=41, Active, not recruiting, Sponsor: Children's Oncology Group
N=24 --> 0 | Trial completion date: Jul 2025 --> Oct 2024 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jul 2025 --> Oct 2024 Trial completion date: Sep 2024 --> Sep 2025
- Leukine (sargramostim) / Partner Therap, Molgradex (molgramostim) / Savara, Nobelpharma
Pulmonary Alveolar Proteinosis; Treatment Update by Clinical Trials (CRYSTAL 2; 3F) - Oct 21, 2024 - Abstract #KATRDIC2024KATRDIC_73;
One Japanese study has shown that GM-CSF (sargramostim) inhalation can improve significantly compared with placebo inhalation (Tazawa, et al...The other global clinical trial of GM-CSF (molgramostim) inhalation could not show the significant effects (Trapnell, et al...This year is epoch making for APAP patients. I would like to show you the history of GM-CSF inhalation therapy during the past 20 years.
- | Leukine (sargramostim) / Partner Therap, Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
Trial completion date: NCI-2018-03732: Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma (clinicaltrials.gov) - Oct 17, 2024
P2, N=42, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
I would like to show you the history of GM-CSF inhalation therapy during the past 20 years. Trial completion date: Sep 2024 --> Sep 2025
- | Leukine (sargramostim) / Partner Therap
Trial primary completion date, Post-transplantation: GM-CSF With Post-Transplant Cyclophosphamide (clinicaltrials.gov) - Oct 17, 2024
P2, N=38, Recruiting, Sponsor: Northside Hospital, Inc.
Trial completion date: Sep 2024 --> Sep 2025 Trial primary completion date: Sep 2024 --> Sep 2025
- | Kimmtrak (tebentafusp-tebn) / Immunocore
New P1/2 trial: Tebentafusp-tebn With LDT in Metastatic UM (clinicaltrials.gov) - Oct 4, 2024
P1/2, N=109, Not yet recruiting, Sponsor: Thomas Jefferson University
- | Leukine (sargramostim) / Partner Therap
Trial completion: Biomarker Assessments of Leukine During Treatment of Parkinson's Disease (clinicaltrials.gov) - Oct 2, 2024
P1, N=7, Completed, Sponsor: University of Nebraska
Trial primary completion date: Sep 2024 --> Sep 2025 Active, not recruiting --> Completed
- Danyelza (naxitamab) - Y / mAbs Therap
EXTENDED NAXITAMAB THERAPY IN REFRACTORY/RELAPSED (R/R) HIGH-RISK NEUROBLASTOMA (HR-NB): A MULTI-CENTER, RETROSPECTIVE CASE SERIES () - Oct 2, 2024 - Abstract #SIOP2024SIOP_1027;
Extended outpatient naxitamab therapy (8-20 cycles) was associated with sustained remission or maintained disease control in heavily pretreated patients with R/R HR-NB. Given the high risk of further relapse, patient/caregivers often requested extended treatment, which was feasible without evidence of unanticipated or cumulative toxicity.
- | Leukine (sargramostim) / Partner Therap
Trial completion date, Trial primary completion date: SESAD: Phase II Trial to Evaluate Safety and Efficacy of GM-CSF/Sargramostim in Alzheimer's Disease (clinicaltrials.gov) - Oct 1, 2024
P2, N=42, Recruiting, Sponsor: University of Colorado, Denver
Given the high risk of further relapse, patient/caregivers often requested extended treatment, which was feasible without evidence of unanticipated or cumulative toxicity. Trial completion date: Jul 2025 --> Oct 2026 | Trial primary completion date: Jul 2025 --> Apr 2026
- | Zeltherva (galinpepimut-S) / SELLAS Life Sciences
Trial completion, Phase classification: WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation (clinicaltrials.gov) - Sep 20, 2024
P1/2, N=20, Completed, Sponsor: Sellas Life Sciences Group
Trial completion date: Jul 2025 --> Oct 2026 | Trial primary completion date: Jul 2025 --> Apr 2026 Unknown status --> Completed | Phase classification: PN/A --> P1/2
- | AST-302 / Aston Sci., EpiThany
Trial completion, Enrollment change, Metastases: WOKVAC: Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission (clinicaltrials.gov) - Sep 19, 2024
P1, N=32, Completed, Sponsor: University of Washington
Unknown status --> Completed | Phase classification: PN/A --> P1/2 Active, not recruiting --> Completed | N=24 --> 32
- | Zolinza (vorinostat) / Merck (MSD), Azedra (iobenguane I 131) / Lantheus, Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
Trial completion date: MIBG With Dinutuximab +/- Vorinostat (clinicaltrials.gov) - Sep 4, 2024
P1, N=45, Active, not recruiting, Sponsor: New Approaches to Neuroblastoma Therapy Consortium
Active, not recruiting --> Completed | N=24 --> 32 Trial completion date: Jun 2024 --> Jun 2025
- | Keytruda (pembrolizumab) / Merck (MSD), SurVaxM (SVN53-67/M57-KLH peptide vaccine) / MimiVax
Trial completion: RESURGe: Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence (clinicaltrials.gov) - Aug 27, 2024
P2, N=41, Completed, Sponsor: David Peereboom
Trial completion date: Jun 2024 --> Jun 2025 Active, not recruiting --> Completed
- | Leukine (sargramostim) / Partner Therap
Journal: Successful subcutaneous desensitization to sargramostim in a pediatric patient. (Pubmed Central) - Aug 24, 2024
Active, not recruiting --> Completed No abstract available
- | Zeltherva (galinpepimut-S) / SELLAS Life Sciences
Trial completion date, Trial primary completion date, Checkpoint inhibition: Using a Targeted Cancer Vaccine (Galinpepimut-S) with Immunotherapy (Nivolumab) in Mesothelioma (clinicaltrials.gov) - Aug 8, 2024
P1, N=10, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
No abstract available Trial completion date: Jul 2024 --> Jul 2025 | Trial primary completion date: Jul 2024 --> Jul 2025
- | Leukine (sargramostim) / Partner Therap, SurVaxM (SVN53-67/M57-KLH peptide vaccine) / MimiVax
Trial completion date, Trial initiation date, Trial primary completion date, Metastases: Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Tumors (clinicaltrials.gov) - Aug 1, 2024
P2, N=132, Not yet recruiting, Sponsor: Roswell Park Cancer Institute
Trial completion date: Jul 2024 --> Jul 2025 | Trial primary completion date: Jul 2024 --> Jul 2025 Trial completion date: Jan 2028 --> Oct 2028 | Initiation date: Jul 2024 --> Oct 2024 | Trial primary completion date: Jan 2027 --> Oct 2027
- | Leukine (sargramostim) / Partner Therap
Trial completion date, Trial primary completion date: Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the Lung (clinicaltrials.gov) - Aug 1, 2024
P1, N=24, Not yet recruiting, Sponsor: Mayo Clinic
Trial completion date: Jan 2028 --> Oct 2028 | Initiation date: Jul 2024 --> Oct 2024 | Trial primary completion date: Jan 2027 --> Oct 2027 Trial completion date: Apr 2025 --> Jul 2025 | Trial primary completion date: Apr 2025 --> Jul 2025
- | Leukine (sargramostim) / Partner Therap, Danyelza (naxitamab-gqgk) - Y / mAbs Therap
New P2 trial: N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma (clinicaltrials.gov) - Jul 29, 2024
P2, N=45, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
- | Leukine (sargramostim) / Partner Therap
Journal: Neuron loss in the brain starts in childhood, increases exponentially with age and is halted by GM-CSF treatment in Alzheimer's disease. (Pubmed Central) - Jul 29, 2024
The ability of GM-CSF treatment to reduce neuronal apoptosis was confirmed in a rat model of AD. These findings suggest that the exponential increase in neurodegeneration with age, accelerated by neuroinflammation, may underlie the contribution of aging to cognitive decline and AD and can be halted by GM-CSF/sargramostim treatment.
- | Keytruda (pembrolizumab) / Merck (MSD), Leukine (sargramostim) / Partner Therap, Yervoy (ipilimumab) / BMS
Enrollment closed, Trial completion date, Trial primary completion date, Metastases: Metastatic Solid Cancer Clinical Trial (clinicaltrials.gov) - Jul 23, 2024
P2, N=32, Active, not recruiting, Sponsor: ImmunSYS, LLC
These findings suggest that the exponential increase in neurodegeneration with age, accelerated by neuroinflammation, may underlie the contribution of aging to cognitive decline and AD and can be halted by GM-CSF/sargramostim treatment. Recruiting --> Active, not recruiting | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
- | AST-301 / University of Washington, Aston Sci., EpiThany
Trial primary completion date: Conerstone3: Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Gastric Cancer (clinicaltrials.gov) - Jul 9, 2024
P2, N=24, Recruiting, Sponsor: Aston Sci. Inc.
Recruiting --> Active, not recruiting | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024 Trial primary completion date: Oct 2023 --> Oct 2025
- | Leukine (sargramostim) / Partner Therap, MVI-816 / Madison Vaccines, Opdivo (nivolumab) / BMS
Trial completion date: NCI-2018-01474: pTVG-HP and Nivolumab in Patients With Non-Metastatic PSA-Recurrent Prostate Cancer (clinicaltrials.gov) - Jul 9, 2024
P2, N=19, Active, not recruiting, Sponsor: University of Wisconsin, Madison
Trial primary completion date: Oct 2023 --> Oct 2025 Trial completion date: Nov 2024 --> Dec 2027
- | Leukine (sargramostim) / Partner Therap, Danyelza (naxitamab) - Y / mAbs Therap
Phase classification, Trial completion date, Trial primary completion date: Study of Chemoimmunotherapy for High-Risk Neuroblastoma (clinicaltrials.gov) - Jul 3, 2024
P1, N=48, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial completion date: Nov 2024 --> Dec 2027 Phase classification: P2 --> P1 | Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Jun 2024 --> Jun 2025
- Leukine (sargramostim) / Partner Therap
Plasma biomarkers of neurodegeneration in the brain (UCH-L1 and NfL) become exponentially higher with age from early childhood, and treatment of Alzheimer (Exhibit (Pennsylvania Convention Center); In-Person) - Jun 19, 2024 - Abstract #AAIC2024AAIC_2784;
Phase classification: P2 --> P1 | Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Jun 2024 --> Jun 2025 These findings suggest that age-associated exponential increases in neurodegeneration may underlie the contribution of aging to cognitive decline, including in AD, and that GM-CSF/sargramostim treatment may halt these effects.
- | Leukine (sargramostim) / Partner Therap
Biomarker, Trial completion date: Biomarker Validation Following Sargramostim Treatment in Parkinson's Disease (clinicaltrials.gov) - Jun 17, 2024
P1, N=11, Active, not recruiting, Sponsor: University of Nebraska
These findings suggest that age-associated exponential increases in neurodegeneration may underlie the contribution of aging to cognitive decline, including in AD, and that GM-CSF/sargramostim treatment may halt these effects. Trial completion date: May 2024 --> Dec 2024
- | AST-301 / University of Washington, Aston Sci., EpiThany
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: Cornerstone001: Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With Breast Cancer (clinicaltrials.gov) - Jun 16, 2024
P2, N=10, Terminated, Sponsor: Aston Sci. Inc.
Trial completion date: May 2024 --> Dec 2024 N=146 --> 10 | Trial completion date: Dec 2025 --> May 2024 | Recruiting --> Terminated | Trial primary completion date: Aug 2025 --> May 2024; Difficulty in recruiting patients
- | neoantigen peptide vaccine / Mayo Clinic, National Cancer Institute
Phase classification, Metastases: PNeoVCA: Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors (clinicaltrials.gov) - Jun 12, 2024
P1/2, N=36, Recruiting, Sponsor: Mayo Clinic
N=146 --> 10 | Trial completion date: Dec 2025 --> May 2024 | Recruiting --> Terminated | Trial primary completion date: Aug 2025 --> May 2024; Difficulty in recruiting patients Phase classification: P1 --> P1/2
- |||| Leukine (sargramostim) / Partner Therap, Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
New P2 trial, Combination therapy: NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial (clinicaltrials.gov) - Jun 9, 2024
P2, N=62, Not yet recruiting, Sponsor: New Approaches to Neuroblastoma Therapy Consortium
- Leukine (sargramostim) / Partner Therap
Inhaled GM-CSF Reduces the Need for Whole Lung Lavage (WLL) and Improves Gas Exchange in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Patients (A3) - May 31, 2024 - Abstract #ERS2024ERS_1052;
No serious adverse events were reported.Conclusions.This long-term, prospective, randomized trial1 demonstrated inhaled sargramostim following WLL reduced the requirement for WLL, improved lung function, and was safe in aPAP patients. WLL plus inhaled sargramostim may be useful as combined therapy for aPAP.1Eur Respir J. 2024; 63(1):2301233.
- | Leukine (sargramostim) / Partner Therap
Biomarker, Trial completion date, Trial primary completion date: Biomarker Validation Following Sargramostim Treatment in Parkinson's Disease (clinicaltrials.gov) - May 13, 2024
P1, N=11, Active, not recruiting, Sponsor: University of Nebraska
- | Keytruda (pembrolizumab) / Merck (MSD), Leukine (sargramostim) / Partner Therap, Yervoy (ipilimumab) / BMS
Enrollment closed, Trial completion date, Trial primary completion date, Metastases: ABSCOPAL 5001: A Phase 2 Trial for Patients With Metastatic Solid Cancer (clinicaltrials.gov) - May 9, 2024
P2, N=32, Active, not recruiting, Sponsor: Rampart Health, L.L.C.
WLL plus inhaled sargramostim may be useful as combined therapy for aPAP.1Eur Respir J. 2024; 63(1):2301233. Recruiting --> Active, not recruiting | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
- | Leukine (sargramostim) / Partner Therap, SurVaxM (SVN53-67/M57-KLH peptide vaccine) / MimiVax
Trial initiation date, Metastases: Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Tumors (clinicaltrials.gov) - May 3, 2024
P2, N=132, Not yet recruiting, Sponsor: Roswell Park Cancer Institute
Recruiting --> Active, not recruiting | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024 Initiation date: Apr 2024 --> Jul 2024
- | Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap, Leukine (sargramostim) / Partner Therap, Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
Trial completion date: Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma (clinicaltrials.gov) - Apr 25, 2024
P3, N=1449, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
- | Leukine (sargramostim) / Partner Therap, Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
Trial completion date, Surgery: Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery (clinicaltrials.gov) - Apr 25, 2024
P1, N=18, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Initiation date: Apr 2024 --> Jul 2024 Trial completion date: Apr 2024 --> Apr 2025
- Leukine (sargramostim) / Partner Therap, Zelboraf (vemurafenib) / Roche
Cutaneous melanoma during pregnancy: Management and real-world outcomes. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_4976;
Melanoma diagnosed during pregnancy can be safely and effectively staged with sentinel lymph node surgery, MRI imaging (PET-MRI vs standard), and CT imaging with shielding without a need for early induction of labor nor a delay in cancer care. Furthermore, we report a patient with stage IV disease treated with vemurafenib during and immunotherapy after pregnancy, indicating that treating stage IV PAM with systemic therapy is a consideration.
- Leukine (sargramostim) / Partner Therap, humanised dinutuximab (Hu14.18K322A) / Essential Pharma, Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
A pilot study of post-consolidation chemoimmunotherapy for high-risk neuroblastoma (ANBL19P1): A report from the Children's Oncology Group. (S100bc) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2740;
P2
Administration of post-consolidation chemoimmunotherapy in pts who underwent tandem ASCT is tolerable and met pre-defined feasibility criteria. The impact of this approach on survival outcomes will be studied in a future COG trial.